- Supported exchanges /
- F /
- G1G.F
Zelira Therapeutics Limited (G1G F) stock market data APIs
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Zelira Therapeutics Limited Financial Data Overview
| 0.49 | |
| 0.49 | |
| - | |
| 0.49 | |
| 0.49 | |
| 0.161-0.62 | |
| 5 179 K | |
| 11 347 K | |
| 94 952 | |
| 0.826 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Zelira Therapeutics Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 94 952
- EBITDA -5 543 669
- Earnings Per Share -1.99
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Zelira Therapeutics Limited Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Zelira Therapeutics Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
